The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast
- 20 July 2007
- journal article
- Published by Wiley in Histopathology
- Vol. 51 (2), 227-238
- https://doi.org/10.1111/j.1365-2559.2007.02754.x
Abstract
To classify MUC1 according to five predefined expression patterns in ductal carcinoma in situ (DCIS) and related clinicopathological parameters, coexpression of other biological markers and prognosis. With a manual tissue arrayer, 92% (n = 80) of the 87 DCIS samples were successfully targeted. Immunohistochemistry was carried out for MUC1, oestrogen receptor (ER), progesterone receptor (PR), Her2/Neu, p53 and cyclin D1. Entire membrane expression was related to Her2/neu negativity (P =0.042). Apical membrane expression was associated with low grade (P = 0.027), Her2/neu negativity (P = 0.014) and PR positivity (P = 0.005). Focal cytoplasmic expression was related to high grade (P = 0.006). Diffuse cytoplasmic expression was associated with high grade (P = 0.004), large tumour size (P = 0.046), Her2/neu positivity (P =0.042) and cyclin D1 positivity (P = 0.002). On the basis of these analyses the four patterns were reclassified as membranous or cytoplasmic expression. On multivariate analysis, cytoplasmic MUC1 expression (hazard ratio 8.5, 95% confidence interval 1.0, 73.0; P = 0.04) was the only independent predictor of local recurrence. Four patterns of MUC1 expression are recognized in DCIS that suggest a relationship to functional differentiation and can be simplified into two types that are clinically relevant and could therefore be helpful in the distinction between different subgroups of DCIS.Keywords
This publication has 30 references indexed in Scilit:
- The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinomaHistopathology, 2007
- Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy GroupJournal of Clinical Oncology, 2006
- Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinomaCancer, 2004
- Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor markerInternational Journal of Gynecologic Cancer, 2002
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.Molecular Biology of the Cell, 1996
- Delayed Mammary Tumor Progression in Muc-1 Null MiceOnline Journal of Public Health Informatics, 1995
- Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.The Journal of cell biology, 1995
- Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival.Journal of Clinical Pathology, 1988
- The hypervariable gene locus PUM, which codes for the tumour associated epithelial mucins, is located on chromosome 1, within the region 1g21–24Annals of Human Genetics, 1987